Department of Obstetrics and Gynecology, Fortaleza University (UNIFOR), Fortaleza-CE, Brazil.
CONCEPTUS - Reproductive Medicine, Fortaleza-CE, Brazil.
Am J Reprod Immunol. 2020 Jun;83(6):e13242. doi: 10.1111/aji.13242. Epub 2020 Apr 18.
Studies have investigated the gestational outcomes of new immunological therapies in the treatment of patients with recurrent implantation failure (RIF) in assisted reproductive technology (ART). The objective of this article is to assess the current state of evidence available in the literature on intrauterine perfusion immunotherapies in women undergoing ART treatments. By considering the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA), the authors performed systematic review by searching the databases of PubMed/MEDLINE and Scopus using the following key words: "recurrent implantation failure," "intrauterine infusion," "Platelet-Rich Plasma (PRP)," "Peripheral Blood Mononuclear Cells (PBMC)," "Granulocyte Colony-Stimulating Factor (G-CSF)," and "Human Chorionic Gonadotropin (hCG)." The authors analyzed the indications and the impact of new immunological therapies with intrauterine infusions on the pregnancy outcomes of patients undergoing ART. PRP, PBMC, G-CSF, and hCG were the four most used immunological therapies with intrauterine infusion. These new therapies appear to improve the results of ART treatments in cases of RIF. However, the small number of studies does not allow definitive conclusions about the effectiveness of these therapies.
研究调查了新的免疫疗法在辅助生殖技术（ART）中治疗复发性植入失败（RIF）患者的妊娠结局。本文的目的是评估目前文献中关于接受 ART 治疗的女性进行宫内灌注免疫疗法的证据现状。通过考虑系统评价和荟萃分析的首选报告项目（PRISMA）指南，作者使用以下关键词在 PubMed/MEDLINE 和 Scopus 数据库中进行了系统评价：“复发性植入失败”、“宫内输注”、“富含血小板的血浆（PRP）”、“外周血单个核细胞（PBMC）”、“粒细胞集落刺激因子（G-CSF）”和“人绒毛膜促性腺激素（hCG）”。作者分析了新的免疫疗法联合宫内输注对接受 ART 治疗的患者妊娠结局的适应证和影响。PRP、PBMC、G-CSF 和 hCG 是四种最常用于宫内输注的免疫疗法。这些新疗法似乎可以改善 RIF 情况下的 ART 治疗结果。然而，由于研究数量较少，尚无法对这些疗法的有效性得出明确结论。
